These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17968428)

  • 1. Temozolomide induces senescence but not apoptosis in human melanoma cells.
    Mhaidat NM; Zhang XD; Allen J; Avery-Kiejda KA; Scott RJ; Hersey P
    Br J Cancer; 2007 Nov; 97(9):1225-33. PubMed ID: 17968428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
    Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
    Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
    Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
    Sato Y; Kurose A; Ogawa A; Ogasawara K; Traganos F; Darzynkiewicz Z; Sawai T
    Cancer Biol Ther; 2009 Mar; 8(5):452-7. PubMed ID: 19305157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
    Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
    Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the mismatch repair system in temozolomide-induced apoptosis.
    D'Atri S; Tentori L; Lacal PM; Graziani G; Pagani E; Benincasa E; Zambruno G; Bonmassar E; Jiricny J
    Mol Pharmacol; 1998 Aug; 54(2):334-41. PubMed ID: 9687575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
    Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
    Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
    Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
    Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.
    Jaiswal AS; Panda H; Law BK; Sharma J; Jani J; Hromas R; Narayan S
    PLoS One; 2015; 10(5):e0123808. PubMed ID: 25933036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
    Filippi-Chiela EC; Thomé MP; Bueno e Silva MM; Pelegrini AL; Ledur PF; Garicochea B; Zamin LL; Lenz G
    BMC Cancer; 2013 Mar; 13():147. PubMed ID: 23522185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
    Xu GW; Mymryk JS; Cairncross JG
    Int J Cancer; 2005 Aug; 116(2):187-92. PubMed ID: 15800902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.
    Wang H; Cai S; Ernstberger A; Bailey BJ; Wang MZ; Cai W; Goebel WS; Czader MB; Crean C; Suvannasankha A; Shokolenkoc I; Wilson GL; Baluyut AR; Mayo LD; Pollok KE
    Clin Cancer Res; 2013 May; 19(10):2699-709. PubMed ID: 23536437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.